Heron Therapeutics, Inc.
corporate_fare Company Profile
Heron Therapeutics, Inc. (NASDAQ:HRTX) is a publicly traded company in the Life Sciences sector. Wiseek has independently scored 20 items for HRTX at importance 7 or higher on its 1–10 market-impact scale. Its most recent item scored 7 or higher is dated 2026-11-09, rated 8/10. Across its 20 most recent items scored 7 or higher, the top rating is 10/10, with 13 rated 8 or above. Recent SEC coverage for HRTX spans 10-Q, 8-K, DEFA14A, DEF 14A.
Recent high-impact activity:
- Heron 10-Q: Q3 Revenue $35.3M, $23.4M Cash, Going-Concern Warning Absent CorMedix Deal
- Heron Posts $35.3M Q3 Revenue, Down 7.8%, With No 2026 Outlook
- Heron Posts Q3 Revenue of $35.3M, Down 7.8%, as CorMedix Asset Sale Looms
- Heron Sells Substantially All Assets to CorMedix for $145M Cash Plus 14.58M Shares
- Heron Withdraws 2026 Guidance as CINVANTI Patent Loss Clouds Outlook
Financial Snapshot
Short Interest & Short Volume
19.54 days to coverFINRA reported short interest of 34,004,069 shares in HRTX as of the October 30, 2026 settlement, a 7.4% decrease from the prior period — about 19.5 days to cover at its recent average daily volume. On November 20, 2026, 57.5% of HRTX volume reported to FINRA trade-reporting facilities was marked short.
Daily short sale volume covers trades reported to FINRA trade-reporting facilities and is not the same as short interest (bi-monthly reported positions). Source: FINRA — FINRA is the owner and source of this short interest and short sale volume data; it may not be redistributed.